GlassScriptPhysician profile
Donald A Wilson
NPI 1306815436
$566.44
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $104 · 2021: $92.55 · 2022: $43.52 · 2023: $195 · 2024: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $242.34 | 2020-2023 | Orilissa, Lo Loestrin Fe |
| Astellas Pharma US INC | $71.90 | 2023 | Veozah |
| Hologic Sales and Service, LLC | $26.34 | 2024 | Myosure Tissue Removal Device, Novasure |
| Sumitomo Pharma America, INC. | $26.27 | 2024 | Myfembree |
| Pfizer INC. | $24.26 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $23.62 | 2024 | Exparel |
| Coopersurgical, INC. | $21.40 | 2024 | Paragard T 380a |
| Daiichi Sankyo INC. | $20.44 | 2020 | |
| Novo Nordisk INC | $20.14 | 2023 | |
| Therapeuticsmd, INC. | $19.86 | 2021 | |
| Monaghan Medical Corporation | $19.66 | 2023 | Aeroeclipse |
| Convatec INC. | $19.08 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.48 | 2023 | Quviviq |
| Medtronic, INC. | $14.65 | 2024 | Truclear |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.